Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France
Korinna Karampampaa Bristol Myers Squibb, Uxbridge, UKCorrespondence[email protected]
https://orcid.org/0000-0002-2578-1865View further author information
https://orcid.org/0000-0002-2578-1865View further author information, Wenjie Zhangb Precision Health, Los Angeles, CA, USAhttps://orcid.org/0000-0001-8301-2821View further author information
https://orcid.org/0000-0001-8301-2821View further author information, Meena Venkatachalamb Precision Health, Los Angeles, CA, USAhttps://orcid.org/0000-0003-4081-225XView further author information
https://orcid.org/0000-0003-4081-225XView further author information, Francois-Emery Cottec Bristol Myers Squibb, Rueil-Malmaison, Francehttps://orcid.org/0000-0002-6758-4552View further author information
https://orcid.org/0000-0002-6758-4552View further author information & Devender Dhandad Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0003-3618-6962View further author information
https://orcid.org/0000-0003-3618-6962View further author information